Liminatus Pharma, Inc. Class A Common Stock
$0.19-1.16%($-0.00)
TickerSpark Score
31/100
20
Valuation
40
Profitability
15
Growth
52
Health
30
Momentum
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a LIMN research report →
52-Week Range0% of range
Low $0.16
Current $0.19
High $33.66
Companyliminatuspharma.com
Liminatus Pharma, Inc. operates as a clinical-stage immuno-oncology company that develops novel cancer therapies. The company is based in LA Palma, California.
- CEO
- Chris Kim
- IPO
- 2025
- Employees
- 3
- HQ
- La Palma, CA, US
Price Chart
-97.02% · this period
Valuation
- Market Cap
- $5.04M
- P/E
- -0.41
- P/S
- 0.00
- P/B
- -33.64
- EV/EBITDA
- -0.42
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 215.73%
- ROIC
- -283.21%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-10,206,517 · -251.43%
- EPS
- $-0.43 · -7.50%
- Op Income
- $-2,967,812
- FCF YoY
- -221.15%
Performance & Tape
- 52W High
- $33.66
- 52W Low
- $0.16
- 50D MA
- $0.20
- 200D MA
- $1.15
- Beta
- 0.74
- Avg Volume
- 3.71M
Get TickerSpark's AI analysis on LIMN
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 30, 25 | Iris Acquisition Holdings LLC | other | 0 |
| Jul 10, 25 | Lemons II Philip Wayne | other | 0 |
| Jul 10, 25 | Baek Richard JaiHwan | other | 0 |
| Apr 30, 25 | KH Feelux Co., Ltd | other | 0 |
| Apr 30, 25 | Valetudo Therapeutics LLC | other | 0 |
| Apr 30, 25 | Lee Eun Sook | other | 0 |
| Apr 30, 25 | Baek Ji Yeon | other | 0 |
| Apr 30, 25 | Kim Chris | other | 0 |
| Apr 30, 25 | Choi Beom Kyu | other | 0 |
| Apr 30, 25 | Yoo Byong Chul | other | 0 |
Our LIMN Coverage
We haven't published any research on LIMN yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate LIMN Report →Similar Companies
ATHE+0.00%
Alterity Therapeutics Limited
$4.27
NNVC+1.89%
NanoViricides, Inc.
$1.62
GBIO+0.00%
Generation Bio Co.
$5.34
MURA+0.00%
Mural Oncology plc
$2.04
EVAX+0.50%
Evaxion Biotech A/S
$4.00
BTAI+0.93%
BioXcel Therapeutics, Inc.
$1.09
JSPR+6.61%
Jasper Therapeutics, Inc.
$0.87
DYAI+2.30%
Dyadic International, Inc.
$0.74